PRESS RELEASE

Paris, May 9, 2023

APPOINTMENT

MATHILDE MEROT JOINS 4P-PHARMA AS DIRECTOR OF REGULATORY AND CLINICAL AFFAIRS

Mathilde Mérot has been appointed Director of Regulatory and Clinical Affairs at 4P-Pharma, a clinical-stage biotechnology company. With more than 10 years of experience in regulatory affairs and clinical trial implementation in the biopharmaceutical sector, she will oversee the clinical team and determine regulatory strategies for the registration of various drug candidates.

Paris, May 9, 2023 - 4P-Pharma, a clinical-stage biotechnology company, announces the appointment of **Mathilde Mérot** as **Director of Regulatory and Clinical Affairs**.

Mathilde Mérot holds a PhD in Pharmacy from the University of Burgundy (Dijon, France) as well as two Master 2 degrees in "Clinical Trials, Drugs and Health Products" (University of Poitiers) and "European and International Regulatory Affairs" (University of Lille). She has more than **10 years of experience** in regulatory affairs and clinical trial implementation in the biopharmaceutical sector.

Her career started in clinical operations at **MSD France**, where she worked on several clinical trials, mainly in oncology and infectious diseases.

In 2017, she joined the Regulatory Affairs department of **INVENTIVA**, a Dijon-based biopharmaceutical company specialized in fibrosis, lysosomal diseases and oncology. She has worked on the international development of several molecules and the international management of their clinical trials, determining the regulatory strategies for the registration of drug candidates.

Determine regulatory strategies for the registration of drug candidates.

In 2022, Mathilde joined POXEL, a Lyon-based biopharmaceutical company specialized in metabolic diseases. There, she was responsible for the regulatory side of clinical trials and helped set up the European regulatory

strategy for the development of several drug candidates including NASH (non-alcoholic steatohepatitis) and orphan diseases.

"I am delighted that Mathilde has joined our company," says **Revital Rattenbach 4P-Pharma CEO**. *"With her experience in regulatory affairs in Europe and the United States, she will be a tremendous asset in helping us overcome the regulatory and clinical challenges associated with our projects. Her expertise will complement ours, in order to develop and bring curative therapies for serious untreated diseases to patients."*

At 4P-Pharma, Mathilde Mérot will supervise the clinical team (internal and external) and determine the regulatory strategies for the registration of the various drug candidates.

"I am delighted to join this team of professionals committed to the development of curative therapies to address unmet medical needs," she says. Through close collaboration with regulatory authorities and clinical teams, we will be able to make a real positive difference for patients with serious untreated diseases."

ABOUT 4P-PHARMA

4P-Pharma is a clinical stage biotech company founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies. The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.

Press contact

Najette Chaib – nchaib@beyondcom.fr 06 18 38 11 14